Buffett Dumps $982 Million in BofA Stock—What Does He Know?

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

Mark Foletta Biography and Net Worth

Director of DexCom

Mark G. Foletta was elected to our Board of Directors in June 2020. Mr. Foletta had been the Chief Financial Officer and Executive Vice President of Tocagen, Inc., a publicly-traded biotechnology company, from February 2017 until its merger with Forte Biosciences in June 2020. Mr. Foletta previously served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from March 2006 through Amylin’s acquisition by Bristol Myers-Squibb Company in August 2012, and as Vice President, Finance and Chief Financial Officer of Amylin from 2000 to 2006. Previously, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. from 1986 to 2000 and served as an Audit Manager with Ernst & Young. From August 2015 to July 2016, Mr. Foletta served as the interim CFO of Biocept, Inc., a public diagnostics company. Mr. Foletta is an independent director of DexCom, Inc., a public medical device company where he also serves as Lead Director, and AMN Healthcare Services, Inc., a public healthcare services company. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara.

What is Mark G. Foletta's net worth?: The estimated net worth of Mark G. Foletta is at least $607,412.52 as of April 21st, 2023. Mr. Foletta owns 8,073 shares of DexCom stock worth more than $607,413 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Foletta may own. Learn More about Mark G. Foletta's net worth.
How do I contact Mark G. Foletta?: The corporate mailing address for Mr. Foletta and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Mark G. Foletta's contact information.
Has Mark G. Foletta been buying or selling shares of DexCom?: Mark G. Foletta has not been actively trading shares of DexCom within the last three months. Most recently, Mark G. Foletta sold 500 shares of the business's stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $562.83, for a transaction totalling $281,415.00. Learn More on Mark G. Foletta's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 28 times. They sold a total of 252,409 shares worth more than $33,128,636.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 9/9/2024.

Mark G. Foletta Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2021	Sell	500	$562.83	$281,415.00
11/1/2021	Sell	500	$626.32	$313,160.00
10/1/2021	Sell	500	$543.09	$271,545.00
10/15/2020	Sell	1,000	$396.82	$396,820.00	895
9/14/2020	Sell	1,000	$394.14	$394,140.00	895
12/3/2019	Sell	1,000	$226.80	$226,800.00
5/15/2019	Sell	1,000	$121.89	$121,890.00	4,052
4/15/2019	Sell	1,000	$118.98	$118,980.00	4,052
3/15/2019	Sell	1,000	$150.28	$150,280.00	4,052
2/15/2019	Sell	1,000	$148.72	$148,720.00	4,052
8/24/2018	Sell	1,000	$137.50	$137,500.00	4,052
11/27/2017	Sell	2,500	$54.95	$137,375.00	4,952
9/7/2016	Sell	1,800	$94.63	$170,334.00

Mark G. Foletta Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $74.46

$74.14

$75.76

50 Day Range

MA: $70.43

$65.68

$76.27

2 Week Range

Now: $74.46

$62.34

$142.00

Volume

3,165,666 shs

Average Volume

3,924,561 shs

Market Capitalization

$29.08 billion

P/E Ratio

44.59

Dividend Yield

N/A

Beta

1.17